The Future of Radioembolization
Transform oncology embolization therapy and improve treatment options available to patients
>40,000
Liver cancer diagnosis each year in the US
>830,000
Global deaths from liver cancer each year
15.6%
5-year overall survival
We must do better.
Liver cancer is one of the leading causes of global cancer deaths with an abysmal 5-year survival of 15.6%. In the latest Annual Report to the Nation from the NIH, Liver cancer is one of four cancers that has shown no improvement in death rates for both men and women in the United States. In addition, in a recent JAMA Oncology publication, Liver cancer is projected to cost the global economy $1.7 trillion by 2050.
One of the most common treatments for liver cancer is radioembolization therapy. Despite decades of commercial traction and strong business fundamentals, radioembolization continues to be a palliative monotherapy with limited patient outcomes.
NED Medical is looking to change the current trajectory of liver disease and aims to provide clinicians and patients with improved treatment options.
Our Technology
CombiSphere
CombiSphere is a Y90 radioembolization therapy made with proprietary materials that provide a unique combination of characteristics that include:
Optimized size & density
Optimized emission activity per particle
Radiopaque
Optimized tumor coverage
Improved Dosimetry
Our Team
• Interventional Radiologist
• 17+ years in clinical practice
• Vascular & Interventional Radiologist
• 15+ years in clinical practice
• Previous CMO and SVP of Clin Dev, R&D and Medical Affairs at Sirtex
• 20+ years of pharma and biotech industry experience
• 20+ years of experience in polymeric materials, drug delivery, and medical devices
• Former Chief of Interventional Radiology at WVU Medicine and at Melrose-Wakefield Hospital / Tufts Medicine